Get the Stockscreener App
8.42
1.63%
0.13
Precision Biosciences Inc stock is traded at $8.42, with a volume of 23,523.
It is up +1.63% in the last 24 hours and down -10.37% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$8.29
Open:
$8.16
24h Volume:
23,523
Relative Volume:
0.39
Market Cap:
$62.07M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-10.40
EPS:
-0.81
Net Cash Flow:
$-100.45M
1W Performance:
+3.25%
1M Performance:
-10.37%
6M Performance:
-19.91%
1Y Performance:
-34.01%
1-Day Range:
$8.155
$8.58
1-Week Range:
$7.97
$9.14
52-Week Range:
$7.97
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Financial Content
(DTIL) Trading Report - Stock Traders Daily
Precision BioSciences stock hits 52-week low at $8.22 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $8.22 - Investing.com
Precision BioSciences begins clinical trial for hepatitis B cure By Investing.com - Investing.com Australia
Precision BioSciences touts gene editing efficiency with ARCUS - Investing.com India
Precision BioSciences touts gene editing efficiency with ARCUS By Investing.com - Investing.com Canada
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - StockTitan
Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Precision BioSciences, Inc. announced that it has received $25.65 million in funding from a group of investors. - Marketscreener.com
Precision BioSciences begins clinical trial for hepatitis B cure - Investing.com
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - BioSpace
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Drops By 7.1% - MarketBeat
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - BioSpace
How the (DTIL) price action is used to our Advantage - Stock Traders Daily
Gene Editing Tools Market Poised for Massive Growth (2024-2031) - openPR
(DTIL) Investment Report - Stock Traders Daily
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - StockTitan
Precision BioSciences files for gene editing trial - Investing.com India
Precision Biosciences files CTAs for PBGENE-HBV for chronic HBV - BioWorld Online
Precision BioSciences files for gene editing trial By Investing.com - Investing.com UK
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B - Business Wire
When (DTIL) Moves Investors should Listen - Stock Traders Daily
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 8.0% - MarketBeat
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet - Yahoo Finance
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution - BioSpace
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock - Yahoo Finance
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma - CGTLive™
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference - Yahoo Finance UK
Precision BioSciences receives $13 million from Imugene - Investing.com India
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):